{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:27:04Z","timestamp":1761488824877},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T00:00:00Z","timestamp":1322697600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Caused by<jats:italic>Mycobacterium leprae<\/jats:italic>(ML), leprosy presents a strong immune-inflammatory component, whose status dictates both the clinical form of the disease and the occurrence of reactional episodes. Evidence has shown that, during the immune-inflammatory response to infection, the growth hormone\/insulin-like growth factor-I (GH\/IGF-I) plays a prominent regulatory role. However, in leprosy, little, if anything, is known about the interaction between the immune and neuroendocrine systems.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the present retrospective study, we measured the serum levels of IGF-I and IGBP-3, its major binding protein. These measurements were taken at diagnosis in nonreactional borderline tuberculoid (NR BT), borderline lepromatous (NR BL), and lepromatous (NR LL) leprosy patients in addition to healthy controls (HC). LL and BL patients who developed reaction during the course of the disease were also included in the study. The serum levels of IGF-I, IGFBP-3 and tumor necrosis factor-alpha (TNF-\u03b1) were evaluated at diagnosis and during development of reversal (RR) or erythema nodosum leprosum (ENL) reaction by the solid phase, enzyme-labeled, chemiluminescent-immunometric method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The circulating IGF-I\/IGFBP-3 levels showed significant differences according to disease status and occurrence of reactional episodes. At the time of leprosy diagnosis, significantly lower levels of circulating IGF-I\/IGFBP-3 were found in NR BL and NR LL patients in contrast to NR BT patients and HCs. However, after treatment, serum IGF-I levels in BL\/LL patients returned to normal. Notably, the levels of circulating IGF-I at diagnosis were low in 75% of patients who did not undergo ENL during treatment (NR LL patients) in opposition to the normal levels observed in those who suffered ENL during treatment (R LL patients). Nonetheless, during ENL episodes, the levels observed in RLL sera tended to decrease, attaining similar levels to those found in NR LL patients. Interestingly, IGF-I behaved contrary to what was observed during RR episodes in R BL patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our data revealed important alterations in the IGF system in relation to the status of the host immune-inflammatory response to ML while at the same time pointing to the circulating IGF-I\/IGFBP-3 levels as possible predictive biomarkers for ENL in LL patients at diagnosis.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1471-2334-11-339","type":"journal-article","created":{"date-parts":[[2011,12,13]],"date-time":"2011-12-13T19:20:55Z","timestamp":1323804055000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Circulating levels of insulin-like growth factor-I (IGF-I) correlate with disease status in leprosy"],"prefix":"10.1186","volume":"11","author":[{"given":"Luciana Silva","family":"Rodrigues","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Andrea","family":"Hacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ximena","family":"Illarramendi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Fernanda Miguens","family":"Castelar Pinheiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Augusto","family":"da Costa Nery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Euzenir Nunes","family":"Sarno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Cristina","family":"Vidal Pessolani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,13]]},"reference":[{"key":"1685_CR1","first-page":"389","volume":"86","author":"WHO","year":"2011","unstructured":"WHO: Global leprosy situations, 2011. Wkly Epidemiol Rec. 2011, 86: 389-400.","journal-title":"Wkly Epidemiol Rec"},{"key":"1685_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1128\/CMR.19.2.338-381.2006","volume":"19","author":"DM Scollard","year":"2006","unstructured":"Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL: The continuing Challenges of Leprosy. Clin Microbiol Rev. 2006, 19: 338-381. 10.1128\/CMR.19.2.338-381.2006.","journal-title":"Clin Microbiol Rev"},{"key":"1685_CR3","first-page":"255","volume":"34","author":"DS Ridley","year":"1966","unstructured":"Ridley DS, Jopling WH: Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966, 34: 255-273.","journal-title":"Int J Lepr Other Mycobact Dis"},{"key":"1685_CR4","doi-asserted-by":"publisher","first-page":"e351","DOI":"10.1371\/journal.pntd.0000351","volume":"2","author":"SL Walker","year":"2008","unstructured":"Walker SL, Nicholls PG, Butlin CR, Nery JAC, Roy HK, Rangel E, Sales AM, Lockwood DNJ: Development and Validation of a Severity Scale for Leprosy Type 1 Reactions. PLoS Negl Trop Dis. 2008, 2: e351-10.1371\/journal.pntd.0000351.","journal-title":"PLoS Negl Trop Dis"},{"key":"1685_CR5","first-page":"190","volume":"65","author":"WH Van Brakel","year":"1994","unstructured":"Van Brakel WH, Khawast IB, Lucas SB: Reactions in leprosy: a epidemiological study of 386 patients in West Nepal. Lepr Rev. 1994, 65: 190-203.","journal-title":"Lepr Rev"},{"key":"1685_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1590\/S0036-46651998000600005","volume":"40","author":"JA Nery","year":"1998","unstructured":"Nery JA, Vieira LM, de Mattos HJ, Sarno EN: Reactional states in multibacilary Hansen disease patients during multidrug therapy. Rev Inst Med Trop S\u00e3o Paulo. 1998, 40: 363-370.","journal-title":"Rev Inst Med Trop S\u00e3o Paulo"},{"key":"1685_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.vetimm.2009.01.013","volume":"130","author":"P Borghetti","year":"2009","unstructured":"Borghetti P, Saleri R, Mocchegiani E, Corradi A, Martelli P: Infection, immunity and the neuroendocrine response. Vet Immunol Immunopathol. 2009, 130: 141-162. 10.1016\/j.vetimm.2009.01.013.","journal-title":"Vet Immunol Immunopathol"},{"key":"1685_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1159\/000180264","volume":"16","author":"AR P\u00e9rez","year":"2009","unstructured":"P\u00e9rez AR, Bottasso O, Savino W: The impact of infectious diseases upon neuroendocrine circuits. Neuroimmunomodulation. 2009, 16: 96-105. 10.1159\/000180264.","journal-title":"Neuroimmunomodulation"},{"key":"1685_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ecl.2006.09.010","volume":"35","author":"D Mesotten","year":"2006","unstructured":"Mesotten D, Van den Berghe G: Changes within the growth hormone\/insulin-like growth factor I\/IGF binding protein axis during critical illness. Endocrinol Metab Clin North Am. 2006, 35: 793-805. 10.1016\/j.ecl.2006.09.010.","journal-title":"Endocrinol Metab Clin North Am"},{"key":"1685_CR10","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2265.2007.02763.x","volume":"66","author":"A Agha","year":"2007","unstructured":"Agha A, Monson JP: Modulation of glucocorticoid metabolism by growth hormone - IGF-1 axis. Clin Endocrionol. 2007, 66: 459-465.","journal-title":"Clin Endocrionol"},{"key":"1685_CR11","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1038\/nrd2359","volume":"6","author":"DR Clemmons","year":"2007","unstructured":"Clemmons DR: Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nature. 2007, 6: 821-833. 10.1038\/nrd2359.","journal-title":"Nature"},{"key":"1685_CR12","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1152\/ajpendo.2000.278.6.E967","volume":"278","author":"RC Baxter","year":"2000","unstructured":"Baxter RC: Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. Am J Physiol Endocrinol Metab. 2000, 278: 967-976.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1685_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10096-008-0576-5","volume":"28","author":"AM Leal","year":"2009","unstructured":"Leal AM, Foss NT: Endocrine dysfunction in leprosy. Eur J Clin Microbiol Infect Dis. 2009, 28: 1-7. 10.1007\/s10096-008-0576-5.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1685_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1590\/S0004-27302010000500008","volume":"54","author":"PW Rosario","year":"2010","unstructured":"Rosario PW: Normal values of serum IGF-1in adults: results from a Brazilian population. Arq Bras Endocrinol Metab. 2010, 54: 477-481. 10.1590\/S0004-27302010000500008.","journal-title":"Arq Bras Endocrinol Metab"},{"key":"1685_CR15","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s000180050237","volume":"54","author":"SC Van Buul-Offers","year":"1998","unstructured":"Van Buul-Offers SC, Kooijman R: The role of growth hormone and insulin-like growth factors in the immune system. Cell Mol Life Sci. 1998, 54: 1083-1094. 10.1007\/s000180050237.","journal-title":"Cell Mol Life Sci"},{"key":"1685_CR16","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1189\/jlb.0404248","volume":"76","author":"R Kooijman","year":"2004","unstructured":"Kooijman R, Coppens A: Insulin-like Growth Factor-I stimulates IL-10 production in human T cells. J Leukoc Biol. 2004, 76: 862-867. 10.1189\/jlb.0404248.","journal-title":"J Leukoc Biol"},{"key":"1685_CR17","doi-asserted-by":"crossref","first-page":"868","DOI":"10.4269\/ajtmh.2006.74.868","volume":"74","author":"L Pocaterra","year":"2006","unstructured":"Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, et al: Clinical course of erythema nodosum leprosum: a 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg. 2006, 74: 868-879.","journal-title":"Am J Trop Med Hyg"},{"key":"1685_CR18","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1590\/S0037-86822004000500003","volume":"37","author":"JG Guerra","year":"2004","unstructured":"Guerra JG, Penna GO, de Castro LCM, Martelli CMT, Stefani MMA, Costa MB: Erythema nodosum leprosum case series report: clinical profile, immunological basis and treatment implemented in health services. Rev Soc Bras Med Trop. 2004, 37: 384-390. 10.1590\/S0037-86822004000500003.","journal-title":"Rev Soc Bras Med Trop"},{"key":"1685_CR19","first-page":"103","volume":"84","author":"EN Sarno","year":"1991","unstructured":"Sarno EN, Grau GE, Vieira LMM, Nery JA: Serum levels of tumor necrosis factor-alpha and interleukin-1\u03b2 during leprosy reactional states. Clin Exp Immunol. 1991, 84: 103-108.","journal-title":"Clin Exp Immunol"},{"key":"1685_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2249.2007.03485.x","volume":"150","author":"A Lyer","year":"2007","unstructured":"Lyer A, Hatta M, Usman R, Luiten S, Oskam L, Faber W, et al: Serum levels of interferon-gamma, tumour necrosis factor-alpha, soluble interleukin-6R and soluble cell activation markers for monitoring response to treatment of leprosy reactions. Clin Exp Immunol. 2007, 150: 210-216. 10.1111\/j.1365-2249.2007.03485.x.","journal-title":"Clin Exp Immunol"},{"key":"1685_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0166-2236(99)01533-7","volume":"23","author":"HD Venters","year":"2000","unstructured":"Venters HD, Dantzer R, Kelly KW: A New Concept in Neurodegeneration: TNF-\u03b1 is a Silencer of Survival Signals. T Neurosci. 2000, 23: 175-180. 10.1016\/S0166-2236(99)01533-7.","journal-title":"T Neurosci"},{"key":"1685_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1086\/509923","volume":"44","author":"B Ranque","year":"2007","unstructured":"Ranque B, Nguyen VT, Vu HT, Nguyen TH, Nguyen NB, Pham XK, et al: Age is an important risk factor for onset and sequelae of reversal reactions in Vietnamese patients with leprosy. Clin Infect Dis. 2007, 44: 33-40. 10.1086\/509923.","journal-title":"Clin Infect Dis"},{"key":"1685_CR23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1046\/j.1365-4362.1998.00381.x","volume":"37","author":"AD Moubasher","year":"1998","unstructured":"Moubasher AD, Kamel NA, Zedan H, Raheem DD: Cytokines in leprosy, I. Serum cytokine profile in leprosy. Int J Dermatol. 1998, 37: 733-740. 10.1046\/j.1365-4362.1998.00381.x.","journal-title":"Int J Dermatol"},{"key":"1685_CR24","doi-asserted-by":"crossref","first-page":"223","DOI":"10.47276\/lr.78.3.223","volume":"78","author":"VA Belgaumkar","year":"2007","unstructured":"Belgaumkar VA, Gokhale NR, Mahajan PM, Bharadwaj R, Pandit DP, Deshpande S: Circulating cytokine profile in leprosy patients. Lepr Rev. 2007, 78: 223-230.","journal-title":"Lepr Rev"},{"key":"1685_CR25","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1097\/00003246-199609000-00006","volume":"24","author":"AC Timmins","year":"1996","unstructured":"Timmins AC, Cotterill AM, Hughes SC, Holly JM, Ross RJ, Blum W, Hinds CJ: Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. Crit Care Med. 1996, 24: 1460-1466. 10.1097\/00003246-199609000-00006.","journal-title":"Crit Care Med"},{"key":"1685_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S1359-6101(98)00022-7","volume":"10","author":"VH Heemskerk","year":"1999","unstructured":"Heemskerk VH, Daemen MA, Buurman WA: Insulin-like growth factor-1 (IGF-1) and growth hormone (GH) in immunity and inflammation. Cytokine Growth Factor Rev. 1999, 10: 5-14. 10.1016\/S1359-6101(98)00022-7.","journal-title":"Cytokine Growth Factor Rev"},{"key":"1685_CR27","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nri1943","volume":"6","author":"RS Hotchkiss","year":"2006","unstructured":"Hotchkiss RS, Nicholson DW: Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol. 2006, 6: 813-822. 10.1038\/nri1943.","journal-title":"Nat Rev Immunol"},{"key":"1685_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.bbi.2006.06.005","volume":"21","author":"AD Rey","year":"2007","unstructured":"Rey AD, Mahuad CV, Bozza VV, Bogue C, Farroni MA, Bay ML, et al: Endocrine and cytokine responses in humans with pulmonary tuberculosis. Brain Behav Immun. 2007, 21: 171-179. 10.1016\/j.bbi.2006.06.005.","journal-title":"Brain Behav Immun"},{"key":"1685_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1046\/j.1365-3083.2000.00703.x","volume":"51","author":"MC Lima","year":"2000","unstructured":"Lima MC, Pereira GM, Rumjanek FD, Gomes HM, D\u00fcppre N, Sampaio EP, et al: Immunological cytokine correlates of prospective immunity and pathogenesis in leprosy. Scand J Immunol. 2000, 51: 419-428. 10.1046\/j.1365-3083.2000.00703.x.","journal-title":"Scand J Immunol"},{"key":"1685_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/1471-2334-9-75","volume":"9","author":"MM Stefani","year":"2009","unstructured":"Stefani MM, Guerra JG, Sousa ALM, Costa MB, Oliveira MLW, Martelli CT, Scollard DM: Potential plasma markers of type 1 and type 2 leprosy reactions: a preliminary report. BMC Infect Dis. 2009, 9: 75-82. 10.1186\/1471-2334-9-75.","journal-title":"BMC Infect Dis"},{"key":"1685_CR31","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1128\/IAI.73.6.3725-3733.2005","volume":"73","author":"AK Anderson","year":"2005","unstructured":"Anderson AK, Chaduvula M, Atkinson SE, Khanolkar-Young S, Jain S, Suneetha L, Suneetha S, et al: Effects of prednisolone treatment on cytokine expression in patients with leprosy type 1 reactions. Infect Immun. 2005, 73: 3725-3733. 10.1128\/IAI.73.6.3725-3733.2005.","journal-title":"Infect Immun"},{"key":"1685_CR32","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.4049\/jimmunol.149.4.1470","volume":"149","author":"M Yamamura","year":"1992","unstructured":"Yamamura M, Wang XH, Ohmen JD, Uyemura K, Rea TH, Bloom BR, et al: Cytokine patterns of immunologically mediated tissue damage. J Immunol. 1992, 149: 1470-1475.","journal-title":"J Immunol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2334-11-339\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-339","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2334-11-339.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T20:34:24Z","timestamp":1713213264000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/1471-2334-11-339"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1685"],"URL":"https:\/\/doi.org\/10.1186\/1471-2334-11-339","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12]]},"assertion":[{"value":"21 June 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"339"}}